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Acute decompensated heart failure (ADHF) is a vulnerable physiological state characterized by congestion, volume 
overload, and diminished end-organ perfusion. Because of the 
decompensated state, active diuresis, and the vasoactive thera-
pies used to treat ADHF, these patients are at risk of devel-
oping hypotension while hospitalized. However, factors that 
contribute to in-hospital hypotension and its relationship with 
clinical outcomes are poorly understood.
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Transient hypotension during hospitalization may diminish 
perfusion to vital organs and lead to end-organ dysfunction 
with unfavorable clinical outcomes. Prior studies have shown 
that large drops in systolic blood pressure (SBP) from base-
line values are associated with declines in renal function in 
ADHF patients.1,2 Declines in renal function have, in turn, 
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Background—Outcomes associated with episodes of hypotension while hospitalized with acute decompensated heart 
failure are not well understood.
Methods and Results—Using data from Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart 
Failure (ASCEND-HF), we assessed factors associated with in-hospital hypotension and subsequent 30-day outcomes. 
Patients were classified as having symptomatic or asymptomatic hypotension. Multivariable logistic regression was used 
to determine factors associated with in-hospital hypotension, and Cox proportional hazards models were used to assess 
the association between hypotension and 30-day outcomes. We also tested for treatment interaction with nesiritide on 
30-day outcomes and the association between in-hospital hypotension and renal function at hospital discharge. Overall, 
1555 of 7141 (21.8%) patients had an episode of hypotension, of which 73.1% were asymptomatic and 26.9% were 
symptomatic. Factors strongly associated with in-hospital hypotension included randomization to nesiritide (odds ratio, 
1.98; 95% confidence interval [CI], 1.76–2.23; P<0.001), chronic metolazone therapy (odds ratio, 1.74; 95% CI, 1.17–
2.60; P<0.001), and baseline orthopnea ( odds ratio, 1.31; 95% CI, 1.13–1.52; P=0.001) or S3 gallop ( odds ratio, 1.21; 
95% CI, 1.06–1.40; P=0.006). In-hospital hypotension was associated with increased hazard of 30-day mortality (hazard 
ratio, 2.03; 95% CI, 1.57–2.61; P<0.001), 30-day heart failure hospitalization or mortality (hazard ratio, 1.58; 95% CI, 
1.34–1.86; P<0.001), and 30-day all-cause hospitalization or mortality (hazard ratio, 1.40; 95% CI, 1.22–1.61; P<0.001). 
Nesiritide had no interaction on the relationship between hypotension and 30-day outcomes (interaction P=0.874 for 
death, P=0.908 for death/heart failure hospitalization, P=0.238 death/all-cause hospitalization).
Conclusions—Hypotension while hospitalized for acute decompensated heart failure is an independent risk factor for 
adverse 30-day outcomes, and its occurrence highlights the need for modified treatment strategies.
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been associated with increases in mortality and rehospital-
ization. However, the independent association of in-hospital 
hypotensive episodes and outcomes has not been well studied.
The Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure (ASCEND-HF) was a large, 
multicenter trial that randomized patients with baseline SBP 
≥100 mm Hg to receive nesiritide or placebo in addition to 
standard care. ASCEND-HF study investigators reported and 
characterized in-hospital episodes of hypotension as symp-
tomatic or asymptomatic and recorded nadir blood pressure 
(BP) values. Overall, nesiritide therapy led to higher rates of 
both symptomatic and asymptomatic hypotension compared 
with placebo, but nesiritide treatment did not change 30-day 
rehospitalization or mortality.3 However, the overall outcomes 
associated with episodes of in-hospital hypotension have not 
yet been examined. To better understand the clinical impli-
cations of in-hospital hypotension, we performed a post hoc 
analysis of ASCEND-HF to examine patient factors associ-
ated with hypotension and the association between hypoten-
sion and 30-day outcomes.
Methods
Study Design
The study design and results of the ASCEND-HF study have been 
previously reported.3,4 Institutional review board approval was ob-
tained locally at all individual sites, and enrolled subjects provided 
informed consent. Briefly, 7141 patients were randomized to nesirit-
ide or placebo within 24 hours of first intravenous therapy for ADHF. 
Study participants were required to have the following: dyspnea at 
rest or minimal activity, 1 or more accompanying signs (respiratory 
rate ≥20 breaths/min or pulmonary congestion or edema with rales 
one-third or greater up the lung fields), and 1 or more objective mea-
sures of heart failure (HF; congestion or edema on chest radiograph, 
B-type natriuretic peptide [BNP] ≥400 pg/mL or N-terminal pro-BNP 
≥1000 pg/mL, pulmonary capillary wedge pressure >20 mm Hg, or 
left ventricular ejection fraction <40% in previously 12 months).4 
Key exclusions relevant to this study were high risk of hypotension 
(systolic pressure <100 mm Hg or 110 mm Hg with use of intravenous 
nitroglycerin), contraindications for vasodilators, unstable dose of in-
travenous vasoactive medications, milrinone or levosimendan therapy 
in the prior 30 days, and dobutamine treatment at ≥5 μg/mg/min.
Hypotension
Because heart failure patients have different baseline blood pressures, 
the trial protocol specified that investigators report hypotension based 
on clinical judgment per routine clinical care compared with ambula-
tory blood pressure. If there was uncertainty about a patient’s baseline 
blood pressure, then the guidance was to classify hypotension based 
on an SBP of <90 mm Hg. Site investigators/clinicians determined 
whether an episode was clinically significant based on duration and 
standard definitions of symptoms, including lightheadedness, diz-
ziness, feeling faint, blurred vision, auditory disturbances (such as 
tinnitus), emesis, or syncope. Clinically significant in duration was 
defined at the discretion of individual site investigators per standard 
of care. Investigators were trained to repeat blood pressure measure-
ments if hypotension occurred and monitor repeat measurements 
until hypotension resolved per standard of care. For the purposes of 
this analysis, site investigators reported the lowest BP and time of 
hypotension for episodes occurring after randomization and before 
hospital discharge. If multiple episodes of either asymptomatic or 
symptomatic hypotension occurred, the investigators reported the 
most severe or lowest blood pressure among episodes. For patients 
who had both symptomatic and asymptomatic hypotension, data from 
the first event were used for further analysis. Routine BP measure-
ments were taken at 0.5, 1, 3, 6, 24, and then every 24 hours thereafter 
postrandomization while on treatment, at the end of treatment, and 
hospital discharge. BP was otherwise monitored according to each 
hospital’s standard practice. We also performed an analysis using a 
numeric definition for hypotension by evaluating 30-day death and 
30-day death or HF hospitalization among patients with SBP <90 
mm Hg after study drug start.
Statistical Analysis
Categorical variables were reported as numbers and percentages, 
and continuous variables were reported as medians with interquartile 
ranges or means±standard deviations. Baseline characteristics were 
compared using the Wilcoxon rank-sum test for continuous variables 
and the χ2 test for categorical variables.
Logistic regression assessed the associations of baseline factors 
with the risk of developing in-hospital hypotension. Baseline charac-
teristics were selected using stepwise selection from a list of candi-
date variables chosen based on clinical review and prior publications 
in similar patient cohorts (see Methods in the Data Supplement).
Time-dependent Cox proportional hazards models were used to 
evaluate the association of in-hospital hypotension and 30-day clini-
cal outcomes, including death, the composite of death or HF hospital-
ization, and the composite of death or all-cause hospitalization. The 
model was adjusted for variables previously found to be associated 
with risk of these outcomes in the ASCEND-HF cohort. These vari-
ables were selected by stepwise logistic regression from a larger list 
of possible clinically relevant variables on 25 imputed data sets. This 
analysis results in age, blood urea nitrogen, sodium, and SBP being 
included for all models. For 30-day mortality/HF hospitalization/all-
cause hospitalization models, the following additional variables were 
included: creatinine, cerebrovascular disease, depression, hospital-
ization in the last year, elevated jugular venous pressure, and chronic 
respiratory disease. The 30-day mortality and 30-day mortality/HF 
hospitalization models additionally included dyspnea with minimal 
exertion, and the 30-day mortality/all-cause hospitalization model 
additionally included baseline weight. We further assessed whether 
there was a differential association of hypotension with outcomes by 
the randomized treatment using an interaction between hypotension 
and nesiritide therapy in adjusted models. The same methods were 
used in the sensitivity analysis, which included all patients who expe-
rienced SBP <90 mm Hg within 24 hours of study drug start.
Last, we assessed the relationship between in-hospital hypoten-
sion and renal function measured by creatinine at discharge or day 
10, whichever came first. Renal function was assessed at prespeci-
fied sampling intervals including at study enrollment, 24 hours, at 
end of study drug infusion, and the earlier of discharge or hospital 
day 10. Given that the main interest was to understand the exposure 
of hypotension as it related to the outcome of renal dysfunction, it 
was important to have a distinct period of time that did not overlap 
because it is difficult to assess the contribution to an outcome if there 
is overlap between exposure and outcome. Therefore, we defined the 
exposure of interest, namely hypotension, within the first 48 hours 
because the highest frequency of hypotension occurred during this 
time period. To have standardized outcomes temporally from the 
exposure of hypotension, renal function which was the outcome of 
interest was assessed at discharge or day 10. This provided informa-
tion on the most recent renal function before discharge. Differences 
in renal function from baseline among those experiencing versus 
not experiencing hypotension in the first 48 hours were assessed by 
linear regression with adjustment for previously identified variables 
shown to be related to baseline renal function in the ASCEND-HF 
cohort (namely blood urea nitrogen, age, SBP, creatinine, potassium, 
and weight gain).
To optimize utilization of the ASCEND-HF cohort for these anal-
yses, multiple imputation was implemented. Those with missing 
baseline data had values imputed using Markov Chain Monte Carlo 
and regression methods. Most variables had <1% missing rate; only 
4 variables had rates >10% missing (namely qualifying episode x-
ray, baseline ejection fraction, New York Heart Association class, 
and baseline QRS duration). In analyses requiring variable selection, 
variables were accepted into the final model if selected in ≥85% of 
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the imputed data sets. Final estimates and associated standard errors 
reflect the combined analysis over 25 imputed data sets and account 
for the reduction in information because of missing values.
Results
Baseline Characteristics
Of the 7141 patients enrolled in the overall trial, 1555 (21.8%) 
patients had an episode of hypotension. Of these, 1136 
(73.1%) had asymptomatic, 302 (19.4%) had symptomatic, 
and 117 (7.5%) had both symptomatic and asymptomatic 
hypotension. Baseline characteristics are listed in Table 1. 
Nearly two-thirds (62.2%) of patients experiencing an episode 
of hypotension were randomized to nesiritide therapy. The 
median systolic hypotensive BP for patients with symptomatic 
and asymptomatic hypotension was 80 mm Hg (interquartile 
range [IQR], 70–87) and 83 mm Hg (IQR, 79–88), respec-
tively. The median time to hypotension was 17.2 hours (IQR, 
5.2–30.8) after randomization with a range from 0 to 394 hours 
(Figure 1). Compared with patients who did not have hypo-
tension, subjects experiencing hypotension had lower base-
line systolic and diastolic BPs, lower weight, higher baseline 
BNP but not NT-pro-BNP, more frequent history of myocar-
dial infarction, more frequent history of atrial and ventricular 
arrhythmia, and less frequent history of preexisting hyperten-
sion. Historical and physical examination findings of volume 
overload such as orthopnea, jugular venous distension, or S3 
gallop were present in a higher percentage of persons who 
experienced hypotension than in those who did not (Table 1). 
The frequency of several baseline medications was statistically 
different among patients with hypotension compared with 
those without hypotension, and regional differences in reported 
incidence of hypotension were also observed (Table 1).
Variables Associated With Hypotension
Stepwise logistic regression was used to identify factors asso-
ciated with a hypotensive episode. On multivariable analysis, 
several variables were predictive of hypotension (Table 2). 
The c-statistic for the final model was 0.708. Randomiza-
tion to nesiritide was associated with hypotension (odds 
ratio [OR], 1.98; 95% confidence interval [CI], 1.76–2.23; 
P<0.001), along with chronic metolazone therapy (OR, 1.74; 
95% CI, 1.17–2.60; P=0.007). However, chronic bumetanide 
therapy (OR, 0.52; 95% CI, 0.35–0.78; P=0.002) and preran-
domization calcium channel blocker therapy (OR, 0.70; 95% 
CI, 0.57–0.85; P<0.001) were less associated with hypoten-
sion. Several patient characteristics such as baseline orthop-
nea (OR, 1.31; 95% CI, 1.13–1.52; P=0.001), baseline S3 
gallop (OR, 1.21; 95% CI, 1.06–1.40; P=0.006), and tempera-
ture >36.4°C (OR, 1.38; 95% CI, 1.12–1.72; P=0.003) were 
associated with hypotension. There was also a significant 
regional association for hypotension (P<0.001). Compared 
with North America, Central European region (OR, 0.49; 
95% CI, 0.39–0.61), Latin American region (OR, 0.78; 95% 
CI, 0.63–0.97), and Asia-Pacific region (OR, 0.63; 95% CI, 
0.54–0.74) had less association with hypotension, whereas 
Western European region had no significant difference (OR, 
1.07; 95% CI, 0.85–1.35). Other variables, such as BNP, NT-
pro-BNP, and prerandomization vasodilator therapy, were 
tested but were not found to be significant after multivariable 
adjustment. Because of concerns regarding colinearity, both 
race and region were tested independently in our regression 
model, and region was a slightly stronger predictor of hypo-
tension than race (c-statistic 0.708 versus 0.702).
Association With Outcomes
Patients who experienced an episode of hypotension during 
hospitalization had a higher 30-day mortality risk (7.1 versus 
2.9% for no hypotension; P<0.001), risk of 30-day all-cause 
mortality or HF hospitalization (15.2 versus 8.4%; P<0.001), 
and risk of 30-day mortality or all-cause hospitalization (21.1 
versus 13.8%; P<0.001; Table 3). Patients with symptom-
atic hypotension had a higher risk of 30-day mortality than 
those with asymptomatic hypotension (11.6% versus 5.6%), 
although there was no major difference for the composite of 
30-day mortality or HF hospitalization (15.4% versus 14.4%) 
or 30-day mortality or all-cause hospitalization (20.5% versus 
20.3%). Cause of death among those with symptomatic and 
asymptomatic hypotension was primarily due to worsening 
heart failure (67.2% among those with asymptomatic hypoten-
sion and 80.8% among those with symptomatic hypotension).
After multivariable adjustment, investigator-reported in-
hospital hypotension was still associated with an increased 
hazard of 30-day mortality (hazard ratio [HR], 2.03; 95% CI, 
1.57–2.61; P<0.001), 30-day mortality or HF hospitalization 
(HR, 1.58; 95% CI, 1.34–1.86; P<0.001), and 30-day mortal-
ity or all-cause hospitalization (HR, 1.40; 95% CI, 1.22–1.61; 
P<0.001; Table 3). To confirm these results using a numeric 
definition of hypotension, we performed an analysis to assess 
adjusted outcomes among patients with SBP<90 mm Hg 
within 24 hours of study drug start. The adjusted outcomes 
using this numeric definition for hypotension (30-day mortal-
ity HR 2.01, 95% CI 1.45–2.78 and 30-day mortality or HF 
hospitalization HR 1.49, 95% CI 1.19–1.87) were similar to 
those reported for investigator-reported hypotension.
To test whether nesiritide therapy affected the relationship 
between hypotension and 30-day outcomes, we tested for the 
interaction between assignment to nesiritide and hypotension 
for 30-day outcomes. No statistical interaction was found for 
the three 30-day outcomes (interaction P=0.874, P=0.908, 
P=0.238 for death, death/HF hospitalization, and death/all-
cause hospitalization), indicating that nesiritide did not alter 
the relationship between hypotension and 30-day outcomes.
Relationship Between Hypotension and Renal 
Function
Of 1555 patients experiencing hypotension, 1303 (83.8%) 
experienced it within the first 48 hours of randomization. 
Among patients experiencing hypotension within the first 
48 hours compared with those not experiencing hypotension 
while hospitalized, creatinine values were similar at baseline 
(1.20 [IQR, 1.00–1.50] versus 1.24 [IQR, 1.00–1.60]) and 
discharge/10 days (1.25 [IQR, 1.00–1.60] versus 1.29 [IQR, 
1.01–1.64]; Figure 2). There was no relationship between 
hypotension in the first 48 hours of randomization and creati-
nine value at discharge/day 10 after multivariable adjustment 
(P=0.366).
 by guest on July 7, 2017
http://circheartfailure.ahajournals.org/
D
ow
nloaded from
 
Patel et al  Hypotension and 30-Day Outcomes  921
Table 1. Baseline Characteristics
Variable Overall Trial (n=7141) No Hypotension (n=5586) Hypotension (n=1555) P Value
Female sex 34.2 34.4 33.8 0.664
Age 67 (56–76) 67 (56–76) 67 (55–77) 0.681
Race 0.063
  White 55.9 55.2 58.4
  Black 15.1 15.4 14.1
  Asian 24.8 25.3 22.8
  Other 4.3 4.2 4.7
Medical history
  Prior MI 34.9 33.9 38.5 0.001
  Hypertension 72.1 74.0 65.5 <0.001
  AF 37.4 36.8 39.7 0.040
  Ventricular tachycardia 8.9 8.2 11.6 <0.001
  PAD 10.4 10.7 9.1 0.058
  Diabetes mellitus 42.7 44.1 37.6 <0.001
  Chronic respiratory disease 16.5 16.0 18.4 0.023
Measurements
  Weight, kg 78 (64–95) 78.7 (65–95.4) 76 (62.6–92.2) <0.001
  Temperature, °C 36.6 (36.3–36.9) 36.6 (36.3–36.8) 36.6 (36.2–36.9) 0.186
  Baseline BP, mm Hg
   Systolic 123 (110–140) 126 (112–140) 115 (105–130) <0.001
   Diastolic 74 (66.0–83.0) 75 (68–85) 70 (63–80) <0.001
  Heart rate, bpm 82 (72–95) 82 (71–95) 82 (73–95) 0.065
  Respiratory rate 23 (21–26) 23 (21–26) 23 (20–26) 0.777
  BNP*, pg/mL 990 (544–1850) 962 (530–1820) 1103 (597–1968) 0.012
  NT-pro-BNP*, pg/mL 4501 (2098–9177) 4461 (2110–9229) 4771 (2041–9081) 0.828
  Creatinine, mg/dL 1.2 (1.0–1.6) 1.2 (1–1.6) 1.2 (1–1.5) 0.598
  BUN, mg/dL 25.8 (18–39.1) 25.3 (18.0–38.1) 26.1 (18–41.1) 0.036
  Baseline sodium, mmol/L 139 (136–141) 139 (136–141) 138 (135–141) <0.001
  EF, % 30 (20–39) 30 (22–40) 28 (20–37) <0.001
  EF ≤40% 79.3 78.5 82.1 0.002
Characteristics
  Orthopnea 76.9 75.9 80.7 <0.001
  JVD, MVR, or S3 gallop 70.5 69.1 75.2 <0.001
  X-ray showing pulmonary congestion 80.7 81.5 77.6 <0.001
Region <0.001
  North America 45.4 43.6 51.8
  Asia Pacific 24.7 25.2 22.9
  Latin America 9.3 9.3 9.4
  Central Europe 13.5 15.2 7.6
  Western Europe 7.1 6.7 8.3
Baseline medications
  ACE inhibitor or ARB 60.8 60.2 62.9 0.056
  β-blocker 58.2 57.3 61.7 0.002
  Aldosterone blocker 27.9 27.0 30.9 0.003
  Loop diuretic 95.1 95.0 95.4 0.576
  Calcium channel blocker 12.9 14.0 9.2 <0.001
  Chronic bumetanide 2.5 2.6 2.2 0.342
  Chronic metolazone 1.7 1.4 2.9 <0.001
  Prerandomization oral/topical nitrate 23.5 24.1 21.4 0.021
  Prerandomization intravenous vasodilator 14.8 15.4 12.7 0.007
Planned in-hospital treatment <0.001
  Nesiritide 49.9 46.5 62.2
  Placebo 50.1 53.5 37.8
  Bolus dose of nesiritide 60.7 64.2 48.0 <0.001
Values represent percentages or medians (interquartile range). BNP values were measured at individual sites, while NT-pro-BNP was measured at a core 
laboratory. ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BP, blood 
pressure; BUN, blood urea nitrogen; EF, ejection fraction; MI, myocardial infarction; and PAD, peripheral arterial disease.
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Discussion
In a large randomized, placebo-controlled trial in patients 
with ADHF, we examined the occurrence and consequences 
of episodic hypotension during hospitalization. Hypoten-
sive episodes were common, occurring in >20% of patients, 
despite trial exclusion of patients who were felt to be at high 
risk for hypotension. While the majority of these episodes 
were asymptomatic, hypotension whether asymptomatic or 
symptomatic was associated with worse 30-day outcomes. 
Therefore, any episode of hypotension in the setting of 
ADHF should be treated as a significant event with subse-
quent strategies of care aimed at mitigating the risk for future 
clinical events.
In patients with ADHF, BP varies considerably during the 
course of hospitalization, and it is established that hypoten-
sion at hospital presentation is associated with poor out-
comes.5–10 However, 75% of patients with ADHF do not have 
low BP at the time of hospitalization, yet they remain at risk 
for hypotension while hospitalized. Partly, this may reflect 
hemodynamic instability from the decompensated state and 
the loss of adrenergic tone, contributed in part by neurohor-
monal blocking agents and vasodilators, which are the main-
stays of evidence-based HF therapy and can lead to substantial 
BP reductions.5,8,9,11 In such cases, physicians often tolerate 
transient hypotension in the hope of improving symptoms and 
long-term outcomes. Prior randomized trials have not inves-
tigated the impact of postrandomization hypotension on sub-
sequent clinical outcomes, and our analysis of ASCEND-HF 
demonstrates that postenrollment, in-hospital hypotension is 
significantly associated with adverse 30-day outcomes.
Although randomization to nesiritide therapy was strongly 
associated with in-hospital hypotension, nesiritide treatment 
had no effect on the association between hypotension and 
30-day outcomes. This suggests that the relationship between 
hypotension and outcomes is independent of treatment. In a 
broader context, this study demonstrates the importance of 
large clinical trials for examining outcomes by highlighting 
that one cannot assume that a linear pathway exists from treat-
ment to a surrogate end point such as hypotension or worsen-
ing renal function to an outcome and that we must fully test 
these relationships to prevent making premature assumptions.
For example, in ADHF patients, hypotension and pas-
sive congestion, neurohormonal activation, oxidative stress, 
and inflammation all combine to promote kidney injury. 
Hypotension may contribute to worsening renal function 
and adverse longitudinal outcomes, as suggested by data 
from Efficacy of Vasopressin Antagonism in Heart Failure: 
Outcome Study with Tolvaptan (EVEREST) showing that 
renal function declined in proportion to the magnitude of SBP 
decrease and data from Pre-RELAX-AHF showing that wors-
ening renal function is an independent predictor of 60- and 
90-day mortality.1,2
 However, this analysis of ASCEND-HF 
failed to show differences in renal function among patients 
with and without episodic hypotension at any time point even 
after adjustment for variables known to affect renal function. 
Although we did not assess the magnitude of SBP change, 
the lengths of hospitalizations among trial participants var-
ied, and therapeutic decisions may have corrected transient 
renal dysfunction, our data show that in-hospital episodes 
of hypotension had no clinically meaningful impact on renal 
function at hospital discharge. It is possible that more fre-
quent serial measurements of renal function or use of highly 
sensitive biomarkers such as cystatin c might have identified 
subtle differences in renal function. Although hypoperfusion 
injury to other organs might explain the association with poor 
outcomes, our data suggest that in-hospital hypotension is a 
clinical marker for HF severity and that other unknown mech-
anisms may have contributed to the poorer outcomes among 
those with hypotension.
Factors associated with hypotension in ADHF have not 
been well-studied and have shown inconsistent results.8,12 In 
this study, nesiritide therapy, age, baseline orthopnea and S3 
Figure 1. Time to first hypotensive episode from study ran-
domization. Time from randomization in hours to any reported 
episode of hypotension among 1555 patients with reported 
hypotension.
Table 2. Multivariable Associations With an Episode of  
In-Hospital Hypotension
Variable OR 95% CI P Value
Age (per 10 y over age >60 y) 1.15 1.07–1.22 <0.001
Measurements
  Temperature >36.4°C (for each degree >36.4°C) 1.38 1.12–1.72 0.003
  SBP ≤120 mm Hg (per each 5 mm Hg increase) 0.79 0.76–0.82 <0.001
  SBP >120 mm Hg (per each 5 mm Hg increase) 0.91 0.88–0.93 <0.001
  Heart rate ≤75 bpm (per 5 beats) 1.10 1.04–1.17 0.001
  Baseline sodium ≤145 mmol/L (per each 5 
mmol/L increase)
0.87 0.82–0.93 <0.001
Characteristics
  Baseline orthopnea 1.31 1.13–1.52 <0.001
  Baseline S3 gallop 1.21 1.06–1.40 0.006
Region (compared with North America) <0. 001
  Asia Pacific 0.63 0.54–0.74
  Central Europe 0.49 0.39–0.61
  Latin America 0.78 0.63–0.97
  Western Europe 1.07 0.85–1.35
Medications
  Randomization to nesiritide 1.98 1.76–2.23 <0.001
  Chronic bumetanide 0.52 0.35–0.78 0.002
  Prerandomization calcium channel blocker 0.70 0.57–0.85 <0.001
  Chronic metolazone 1.74 1.17–2.60 0.007
CI indicates confidence interval; OR, odds ratio; and SBP, systolic blood 
pressure.
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gallop, and chronic metolazone therapy were found to con-
tribute to the risk of hypotension. Orthopnea and S3 gallop 
are symptoms and signs of congestion and volume over-
load and may identify persons that have a poor prognosis.7,13 
Moreover, chronic metolazone therapy is usually reserved for 
patients with refractory volume overload who may have more 
advanced HF. Hence, patients who have more severe illness 
may be at higher risk for hypotension. In addition, univari-
ate descriptive statistics indicated that there was less use of 
nesiritide bolus and prerandomization intravenous vasodila-
tors among those experiencing hypotension, while preran-
domization calcium channel blocker therapy was among 
variables associated with less hypotension. This could reflect 
confounding by indication, whereby patients with preexisting 
hypertension or higher baseline blood pressure may be more 
likely to receive afterload-reducing therapies and possibly 
less susceptible to hypotension. Taken in concert, we suspect 
that patients who seem to have unfavorable clinical indicators 
may be less likely to receive therapies such as calcium chan-
nel blockers or intravenous vasodilators because of concerns 
for adverse effects such as hypotension. Such treatment bias 
agrees with our hypothesis and study findings that patients 
with prominent physical findings of volume overload are more 
likely to have hypotension.
Regional differences in this global trial deserve comment, 
with Central European, Latin American, and Asia-Pacific 
regions showing less association with hypotension. In our 
regression models, we did assess for colinearity between race 
and region; region was more strongly associated with report-
ing of hypotensive episodes than race. Regional variations in 
practice patterns and patient demographics have previously 
been observed. For example, the multinational EVEREST trial 
found that there was significant variation in medical, interven-
tional, and device therapies across different global regions.14 
In addition, South America and Eastern Europe both tended to 
enroll younger patients, and Eastern Europe reported the high-
est baseline SBP, highest baseline EF, and better baseline renal 
function values than other regions, suggesting that their over-
all population in the EVEREST trial was healthier at study 
enrollment. As such, Eastern Europe had the lowest adjusted 
rates of cardiovascular death and HF hospitalization.14 Also, 
data from the ADHERE (Acute Decompensated Heart Failure 
Registry)-International Asia-Pacific registry showed that the 
Asia-Pacific region tended to have higher use of inotropes and 
a potentially less comorbid population of patients than other 
parts of the world, with less reported prevalence of coronary 
disease, chronic kidney disease, and atrial fibrillation than 
similar observational cohorts in North America and Europe.15 
These differences in patient populations and treatment pat-
terns could have had an impact on real or reported episodes 
of hypotension and highlight the importance of considering 
regional differences in the interpretation of clinical trial data.
Implications
Our results show that in-hospital hypotension is associated 
with increased 30-day hospitalization and mortality, regard-
less of study drug assignment. Furthermore, these observations 
suggest that individuals who have hemodynamic instabil-
ity are at high risk for subsequent adverse outcomes. This is 
important because many of the therapies that are currently 
used or are being studied for ADHF affect systemic vascular 
resistance and can induce hypotension. Many trials of vaso-
dilator therapies and inotropes for ADHF have shown neutral 
or negative results,3,16,17 perhaps at least partially because of 
the association between in-hospital hypotension and adverse 
outcomes. Taking a broad interpretation, we think physi-
cians should use caution when using or studying vasoactive 
therapies that can lower BP, with a focus on avoidance, early 
detection, and correction of hypotension. Although it is easy 
to ignore an asymptomatic episode of hypotension, the strong 
association of hypotension with adverse 30-day outcomes 
should give pause and compel a thoughtful, tailored approach 
to risk stratify and mitigate every patients’ risk for negative 
outcomes, such as optimization of neurohormonal therapies 
and device therapies before hospital discharge and early post-
hospital follow-up. Future clinical trials and clinical registries 
should incorporate data collection for inpatient hypotensive 
episodes to further clarify the association between episodic 
hypotension and unfavorable outcomes.
Table 3. Adjusted Outcomes in Patients With and Without Hypotension*
Outcome Total No Hypotension Hypotension Adjusted HR 95% CI Cox P Value
30-Day mortality 273/7118 (3.8) 162/5565 (2.9) 111/1553 (7.1) 2.03 1.57–2.61 <0.001
30-Day mortality or HF hospitalization 686/6938 (9.9) 455/5422 (8.4) 231/1516 (15.2) 1.58 1.34–1.86 <0.001
30-Day mortality or all-cause hospitalization 1067/6942 (15.4) 747/5424 (13.8) 320/1518 (21.1) 1.40 1.22–1.61 <0.001
Values presented as n/N (%), unless otherwise indicated. Please see Methods section for adjustment variables. CI indicates confidence interval; HF, 
heart failure; and HR, hazard ratio.
*Test for interaction of nesiritide on relationship of in-hospital hypotension and 30-day outcomes: 30-day mortality, P=0.874; 30-day mortality/HF 
hospitalization, P=0.908; 30-day mortality/all-cause hospitalization, P=0.238.
Figure 2. Median creatinine values among patients with versus 
without hypotension. Values represent the median creatinine val-
ues at various timepoints among the 1303 patients experiencing 
hypotension within 48 hours of randomization. Error bars repre-
sent interquartile range.
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Study Limitations
Several limitations for this study must be acknowledged. This 
is a secondary analysis of the ASCEND-HF study, which 
was not specifically designed to study the effects of hypo-
tension on outcomes. Therefore, this study is observational 
and describes associations among treatment, hypotension, 
and outcomes. No causality can be proven, so the results are 
hypothesis-generating. Nevertheless, because hypotension is 
associated with adverse outcomes and nesiritide is strongly 
associated with hypotension, residual concern for an asso-
ciation between nesiritide-induced hypotension and adverse 
outcomes remains.18–22 Although patients with symptomatic 
hypotension had a higher risk of 30-day mortality than those 
with asymptomatic hypotension, there was no major difference 
in the composite of 30-day mortality/all-cause or HF hospi-
talization, suggesting that there was perhaps a higher rate of 
rehospitalization among those with asymptomatic than symp-
tomatic hypotension. The reasons for similar risk for the com-
posite may have been because of differences in mortality and 
length of stay or from play of chance for this subgroup analy-
sis. Patients with symptomatic hypotension had greater 30-day 
mortality (11.6% versus 5.6%) and longer lengths of stay 
(median 7 days, IQR 4–13 versus median 6 days, IQR 4–10) 
than those with asymptomatic hypotension. Because length of 
stay was shorter and mortality was greater among those with 
symptomatic hypotension, the exposure period for risk of read-
mission was shorter, possibly leading to similar rates for the 
composite of death/readmission at 30 days. Also, hypotension 
was defined by site investigators relative to baseline clinical 
status, which may have affected reporting of events. Neverthe-
less, our sensitivity analysis showed that patients with an SBP 
<90 mm Hg within 24 hours of study drug start have similar 
adjusted outcomes as patients with investigator-reported hypo-
tension, which further supports that low blood pressure while 
hospitalized with ADHF is associated with poor outcomes. 
In addition, even though adjusted analysis was performed to 
minimize the possibility of confounders, all confounding fac-
tors may not have been identified. Finally, because ASCEND-
HF was a large study, baseline differences in patients with and 
without hypotension may have been statistically different with-
out being clinically meaningful, so caution must be used when 
interpreting the results.
Summary
Hypotension is common during hospitalization for ADHF 
and is an important, independent predictor of adverse 30-day 
outcomes. Several patient factors such as concurrent medica-
tion use and severity of HF are associated with the risk of 
hypotension. In-hospital hypotension should be more widely 
recognized as an unfavorable prognostic factor, regardless of 
the cause for hypotension.
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CLINICAL PERSPECTIVE
Acute decompensated heart failure patients are at risk of developing hypotension while hospitalized. Nevertheless, the 
incidence, clinical outcomes, and patient factors that contribute to hypotension among hospitalized acute decompensated 
heart failure patients are poorly understood. We used data from The Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure (ASCEND-HF) to determine factors associated with in-hospital hypotension and the associa-
tion between hypotension and 30-day outcomes. Hypotensive episodes were common, occurring in 21.8% (1555/7141) of 
patients despite trial exclusion of patients who were thought to be high risk for hypotension. While the majority of these epi-
sodes were asymptomatic (73.1%), hypotension whether asymptomatic or symptomatic was associated with worse 30-day 
outcomes (30-day mortality risk [7.1% versus 2.9% for no hypotension; P<0.001], risk of 30-day all-cause mortality or heart 
failure hospitalization [15.2% versus 8.4%; P<0.001], and risk of 30-day mortality or all-cause hospitalization [21.1% ver-
sus 13.8%; P<0.001]). These differences remained significant after multivariable adjustment. Hypotension within the first 48 
hours of hospitalization had no effect on renal function at hospital discharge/day 10, suggesting that end-organ hypoperfu-
sion did not fully explain the higher incidence of adverse outcomes. Instead, patient factors that may be associated with poor 
outcomes such as age, baseline orthopnea or S3 gallop, and chronic metolazone therapy were associated with hypotension. 
In-hospital hypotension may therefore be a marker for patients with poor prognosis. Further work is needed to identify these 
patients early so that a more thoughtful, tailored approach can be pursued to optimize outcomes.
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Supplemental Material 
 
Supplemental Methods: 
For logistic regression analyses, the following variables were tested in the initial logistic regression for 
30-day outcomes: Age; baseline atrial fibrillation/atrial flutter, coronary artery bypass graft, 
cerebrovascular disease, hypertension, chronic liver disease, peripheral vascular disease, ventricular 
tachycardia, myocardial infarction, chronic respiratory disease, creatinine, potassium, sodium, 
temperature, blood urea nitrogen, hemoglobin; history of cancer in the past 5 years, depression, dialysis, 
diabetes, coronary artery disease; systolic and diastolic blood pressure; sex; ethnicity; dyspnea; peripheral 
edema; weight; jugular venous distension; pulmonary congestion; S3 gallop; orthopnea; hospitalization in 
prior year; paroxysmal nocturnal dyspnea; heart rate; respiratory rate; weight gain; height; x-ray showing 
pulmonary edema; NYHA class prior to decompensation; mitral valve regurgitation; baseline QRS 
duration; race; and smoking status. 
 The following additional variables were tested in the logistic regression analysis assessing 
variables associated with hypotension: baseline ejection fraction or major cardiac surgery; prior 
implantable cardioverter-defibillator (ICD), cardiac resynchronization therapy, percutaneous coronary 
intervention, or pacemaker; pre-randomization aldosterone antagonist, aspirin, aspirin, calcium-channel 
blocker, clopidogrel, hydralazine, anticoagulant, oral/topical nitrate, ACE-I or angiotensin receptor 
blocker, beta-blocker, digoxin, nitroprusside, inotropes; chronic use of bumetanide, chlorthiazide, 
furosemide, metolazone, torsemide, or other thiazide diuretic; time to randomization from hospital arrival; 
hour of presentation at night; hour of presentation on weekend; region; BNP; NT-pro-BNP; 
randomization to nesiritide. 
